Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epigenetics in breast cancer therapy—New strategies and future nanomedicine perspectives

  • Buocikova, Verona
  • Ríos-Mondragón, Iván
  • Pilalis, Eleftherios
  • Chatziioannou, Aristotelis
  • Miklikova, Svetlana
  • Mego, Michal
  • Pajuste, Karlis
  • Rucins, Martins
  • El Yamani, Naouale
  • Longhin, Eleonora Marta
  • Sobolev, Arkadij
  • Freixanet, Muriel
  • Puntes, Víctor F.
  • Plotniece, Aiva
  • Dusinska, María
  • Cimpan, Mihaela Roxana
  • Gabelova, Alena
  • Smolkova, Bozena
This article belongs to the Special Issue Epigenetic Therapy: The State of Play in Highly Aggressive Diseases., Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics., This research was funded by ERA-NET EuroNanoMed II INNOCENT, by the Slovak Research and Development Agency (APVV), grant No. APVV-16-0010, APVV-16-0178, by the European Union’s Horizon 2020 research and innovation program under grant agreement No. 857381, project VISION (Strategies to strengthen scientific excellence and innovation capacity for early diagnosis of gastrointestinal cancers), by ERA-NET EuroNanoMed III CELLUX, H2020-NMBP-TO-IND-2019 SABYDOMA, contract No. 862296 and by Scientific Grant Agency (VEGA), contracts No. 2/0271/17, 2/0138/20 and 2/0052/18., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening

  • Kohl, Yvonne
  • Biehl, Margit
  • Spring, Sarah
  • Hesler, Michelle
  • Ogourtsov, Vladimir
  • Todorovic, Miomir
  • Owen, Joshua
  • Elje, Elisabeth
  • Kopecka, Kristina
  • Moriones, Oscar Hernando
  • Bastús, Neus G.
  • Simon, Peter
  • Dubaj, Tibor
  • Rundén-Pran, Elise
  • Puntes, Víctor F.
  • William, Nicola
  • Briesen, Hagen von
  • Wagner, Sylvia
  • Kapur, Nikil
  • Mariussen, Espen
  • Nelson, Andrew
  • Gabelova, Alena
  • Dusinska, María
  • Velten, Thomas
  • Knoll, Thorsten
Microfluidic technology is a valuable tool for realizing more in vitro models capturing cellular and organ level responses for rapid and animal-free risk assessment of new chemicals and drugs. Microfluidic cell-based devices allow high-throughput screening and flexible automation while lowering costs and reagent consumption due to their miniaturization. There is a growing need for faster and animal-free approaches for drug development and safety assessment of chemicals (Registration, Evaluation, Authorisation and Restriction of Chemical Substances, REACH). The work presented describes a microfluidic platform for in vivo-like in vitro cell cultivation. It is equipped with a wafer-based silicon chip including integrated electrodes and a microcavity. A proof-of-concept using different relevant cell models shows its suitability for label-free assessment of cytotoxic effects. A miniaturized microscope within each module monitors cell morphology and proliferation. Electrodes integrated in the microfluidic channels allow the noninvasive monitoring of barrier integrity followed by a label-free assessment of cytotoxic effects. Each microfluidic cell cultivation module can be operated individually or be interconnected in a flexible way. The interconnection of the different modules aims at simulation of the whole-body exposure and response and can contribute to the replacement of animal testing in risk assessment studies in compliance with the 3Rs to replace, reduce, and refine animal experiments., T.K. and Y.K. contributed equally to this work. The authors thank Frank Bauerfeld for system assembly and electrical testing, Werner Haberer for assembly of the microfluidic cartridges, Axel Brenner for the fabrication of the silicon micro cavity chips, Hoffman La Roche for providing the Ro 19-8022, NorGenoTech for providing the Fpg enzyme, and Karen Steenson for proofreading. This research was funded by the European Commission under the Horizon2020 programme (HISENTS, Grant Agreement No. 685817 and VISION, Grant Agreement No. 857381); and by the Norwegian Research Council Norway (RCN) via the European Research Area Network (ERA-NET) EuroNanoMed II project INNOCENT (RCN 271075) and the ERA-NET EuroNanoMed III project Graphene-encapsulated magnetic nanoparticles (RCN 246672/O70). K.K. received Short Term Scientific Mission Grant (ID 42926) under COST Action CA 17140 “Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology). E.E. received funding from the Norwegian Research Council (272412/F40). O.H.M. received funding from the Spanish Ministry of Economy and Competitiveness (SEV-2013-0295-17-3).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival

  • Earl, Julie
  • Barreto, Emma
  • Castillo, María E.
  • Fuentes, Raquel
  • Rodríguez-Garrote, Mercedes
  • Ferreiro, Reyes
  • Reguera, Pablo
  • Muñoz, Gloria
  • García-Seisdedos, David
  • Sainz, Bruno Jr.
  • Malats, Núria
  • Carrato, Alfredo
© 2021 by the authors., Pancreatic ductal adenocarcinoma (PDAC) presents many challenges in the clinic and there are many areas for improvement in diagnostics and patient management. The five-year survival rate is around 7.2% as the majority of patients present with advanced disease at diagnosis that is treatment resistant. Approximately 10–15% of PDAC cases have a hereditary basis or Familial Pancreatic Cancer (FPC). Here we demonstrate the use of circulating free DNA (cfDNA) in plasma as a prognostic biomarker in PDAC. The levels of cfDNA correlated with disease status, disease stage, and overall survival. Furthermore, we show for the first time via BEAMing that the majority of hereditary or familial PDAC cases (around 84%) are negative for a KRAS somatic mutation. In addition, KRAS mutation negative cases harbor somatic mutations in potentially druggable genes such as KIT, PDGFR, MET, BRAF, and PIK3CA that could be exploited in the clinic. Finally, familial or hereditary cases have a longer overall survival compared to sporadic cases (10.2 vs. 21.7 months, respectively). Currently, all patients are treated the same in the clinic with cytotoxic agents, although here we demonstrate that there are different subtypes of tumors at the genetic level that could pave the way to personalized treatment., This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I+D+i 2013– 2016): ISCIII (PI09/02221, PI12/01635, PI15/02101, and PI18/0135) and co-financed by the European Development Regional Fund “A way to achieve Europe” (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073), La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016), Fundación Mutua Madrileña (FMM) / XVI Convocatoria de Ayudas a la Investigación en Salud 2019 and Asociación Cáncer de Páncreas (ACanPan); Asociación Española de Pancreatología (AESPANC) / IV Becas de Investigación Carmen Delgado/Miguel Pérez-Mateo 2019. The European Union’s Horizon 2020 research and innovation program under grant agreement No 857381, project VISION (Strategies to strengthen scientific excellence and innovation capacity for early diagnosis of gastrointestinal cancers)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacokinetics, biodistribution, and biosafety of pegylated gold nanoparticles in vivo

  • Kozics, Katarina
  • Sramkova, Monika
  • Kopecka, Kristina
  • Begerova, Patricia
  • Manova, Alena
  • Krivošíková, Zora
  • Sevcikova, Zuzana
  • Líšková, Aurélia
  • Rollerova, Eva
  • Dubaj, Tibor
  • Puntes, Víctor F.
  • Wsolova, Ladislava
  • Simon, Peter
  • Tulinská, Jana
  • Gabelova, Alena
Despite the obvious advantages of gold nanoparticles for biomedical applications, controversial and incomplete toxicological data hamper their widespread use. Here, we present the results from an in vivo toxicity study using gold nanoparticles coated with polyethylene glycol (PEG-AuNPs). The pharmacokinetics and biodistribution of PEG-AuNPs were examined in the rat’s liver, lung, spleen, and kidney after a single i.v. injection (0.7 mg/kg) at different time intervals. PEG-AuNPs had a relatively long blood circulation time and accumulated primarily in the liver and spleen, where they remained for up to 28 days after administration. Increased cytoplasmic vacuolation in hepatocytes 24 h and 7 days after PEG-AuNPs exposure and apoptotic-like cells in white splenic pulp 24 h after administration has been detected, however, 28 days post-exposure were no longer observed. In contrast, at this time point, we identified significant changes in lipid metabolism, altered levels of liver injury markers, and elevated monocyte count, but without marked biological relevance. In blood cells, no DNA damage was present in any of the studied time intervals, with the exception of DNA breakage transiently detected in primary kidney cells 4 h post-injection. Our results indicate that the tissue accumulation of PEG-AuNPs might result in late toxic effects., This paper is supported by European Union’s Horizon 2020 research and innovation program under grant agreement No. 857381, project VISION (Strategies to strengthen scientific excellence and innovation capacity for early diagnosis of gastrointestinal cancers), project HISENTS No. 685817, VEGA grants 2/0055/20, 2/0121/21.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro—In Vivo Correlation

  • Dubaj, Tibor
  • Kozics, Katarina
  • Sramkova, Monika
  • Manova, Alena
  • Bastús, Neus G.
  • Moriones, Oscar Hernando
  • Kohl, Yvonne
  • Dusinska, María
  • Rundén-Pran, Elise
  • Puntes, Víctor F.
  • Nelson, Andrew
  • Gabelova, Alena
  • Simon, Peter
Data suitable for assembling a physiologically-based pharmacokinetic (PBPK) model for nanoparticles (NPs) remain relatively scarce. Therefore, there is a trend in extrapolating the results of in vitro and in silico studies to in vivo nanoparticle hazard and risk assessment. To evaluate the reliability of such approach, a pharmacokinetic study was performed using the same polyethylene glycol-coated gold nanoparticles (PEG-AuNPs) in vitro and in vivo. As in vitro models, human cell lines TH1, A549, Hep G2, and 16HBE were employed. The in vivo PEG-AuNP biodistribution was assessed in rats. The internalization and exclusion of PEG-AuNPs in vitro were modeled as first-order rate processes with the partition coefficient describing the equilibrium distribution. The pharmacokinetic parameters were obtained by fitting the model to the in vitro data and subsequently used for PBPK simulation in vivo. Notable differences were observed in the internalized amount of Au in individual cell lines compared to the corresponding tissues in vivo, with the highest found for renal TH1 cells and kidneys. The main reason for these discrepancies is the absence of natural barriers in the in vitro conditions. Therefore, caution should be exercised when extrapolating in vitro data to predict the in vivo NP burden and response to exposure., This research was funded by the European Commission under the Horizon 2020 programme (HISENTS, Grant Agreement No. 685817 and VISION, Grant Agreement No. 857381). Financial support from the Structural Funds of EU by implementation of the project “Strategic research in SMART monitoring, treatment, and prevention against coronavirus (SARS-CoV-2)”, ITMS 2014+ code NFP313011ASS8 co-financed by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival

  • Urbanova, María
  • Cihova, Marina
  • Buocikova, Verona
  • Slopovsky, Jan
  • Dubovan, Peter
  • Pindak, Daniel
  • Tomas, Miroslav
  • García-Bermejo, María Laura
  • Rodríguez-Garrote, Mercedes
  • Earl, Julie
  • Kohl, Yvonne
  • Kataki, Agapi
  • Dusinska, María
  • Sainz, Bruno Jr.
  • Smolkova, Bozena
  • Gabelova, Alena
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers worldwide, primarily due to its robust desmoplastic stroma and immunosuppressive tumor microenvironment (TME), which facilitate tumor progression and metastasis. In addition, fibrous tissue leads to sparse vasculature, high interstitial fluid pressure, and hypoxia, thereby hindering effective systemic drug delivery and immune cell infiltration. Thus, remodeling the TME to enhance tumor perfusion, increase drug retention, and reverse immunosuppression has become a key therapeutic strategy. In recent years, targeting epigenetic pathways has emerged as a promising approach to overcome tumor immunosuppression and cancer progression. Moreover, the progress in nanotechnology has provided new opportunities for enhancing the efficacy of conventional and epigenetic drugs. Nano-based drug delivery systems (NDDSs) offer several advantages, including improved drug pharmacokinetics, enhanced tumor penetration, and reduced systemic toxicity. Smart NDDSs enable precise targeting of stromal components and augment the effectiveness of immunotherapy through multiple drug delivery options. This review offers an overview of the latest nano-based approaches developed to achieve superior therapeutic efficacy and overcome drug resistance. We specifically focus on the TME and epigenetic-targeted therapies in the context of PDAC, discussing the advantages and limitations of current strategies while highlighting promising new developments. By emphasizing the immense potential of NDDSs in improving therapeutic outcomes in PDAC, our review paves the way for future research in this rapidly evolving field., This research was funded by the European Union’s Horizon 2020 research and innovation program under grant agreement No 857381/VISION, the Spanish Biomedical Research Network in Cancer CIBERONC (CB16/12/00446), from the Slovak Research and Development Agency (APVV-21-0197, APVV-20-0143) and TRANSCAN-2 Program ERA-NET JTC 2017 “Translational research on rare cancers” within the project NExT., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gold and titania nanoparticles accumulated in the body induce late toxic effects and alterations in transcriptional and miRNA landscape

  • Soltysova, Andrea
  • Ludwig, Nicole
  • Diener, Caroline
  • Sramkova, Monika
  • Kozics, Katarina
  • Jakic, Kristina
  • Balintova, Lucia
  • Bastús, Neus G.
  • Hernando Moriones, Oscar
  • Liskova, Aurelia
  • Krivosikova, Zora
  • Rollerova, Eva
  • Manova, Alena
  • Dubaj, Tibor
  • Puntes, Víctor F.
  • Simon, Peter
  • Wsolova, Ladislava
  • Tulinska, Jana
  • Smolkova, Bozena
  • Meese, Eckart
  • Gabelova, Alena
This article is part of the themed collection: Recent Open Access Articles., The growing production of nanomaterials and their presence in consumer products raises fear about their impact on human health and the environment. Of particular concern are those nanomaterials that exhibit poor excretion and tend to accumulate in living organisms. Our study investigated the potential adverse biological effects of residual gold and titania nanoparticles (PEG-AuNPs and TiO2NPs) 28 days after a single intravenous administration in rats. To comprehensively assess the potential health hazard of these metal nanoparticles (MNP), toxicological and transcriptomic analyses were employed. The liver was the primary organ of the MNP deposition, causing a reduction in the relative liver weight compared to unexposed animals. Concurrently, changes in serum biomarkers indicative of hepatic dysfunction and hematological and immunological alternations were determined. Integrated transcriptomic analysis unveiled exposure-induced effects on the rats' lungs, liver, and kidneys. The hepatic tissue, particularly in PEG-AuNPs-exposed rats, exhibited a noteworthy prevalence of deregulated genes, with functional classification spanning lipid metabolism, cell cycle, and cell proliferation pathways. Although the number of deregulated miRNAs was relatively modest compared to mRNA expression changes, both types of MNPs deregulated miR-203a, associated with liver injury, and miR-18a-5p and miR-32-5p linked to kidney damage. This study underscores the imperative for a more exhaustive biosafety assessment of poorly soluble MNPs that tend to deposit in the body. Such investigations are crucial for delineating the potential risks of these nanomaterials and guiding the development of adequate safety measures in their production and usage., This paper was supported by the European Union's Horizon 2020 research and innovation program under GA No. 857381 (VISION project) and GA No. 685817 (HISENTS project), DAAD project (Epigenotoxicity of nanomaterials), and APVV 16-0579 (BIONANOGOLD project) and CAS-SAS-2022-14 project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A template wizard for the cocreation of machine-readable data-reporting to harmonize the evaluation of (nano)materials

  • Jeliazkova, Nina
  • Longhin, Eleonora
  • El Yamani, Naouale
  • Rundén-Pran, Elise
  • Moschini, Elisa
  • Serchi, Tommaso
  • Vrček, Ivana Vinković
  • Burgum, Michael J.
  • Doak, Shareen H.
  • Cimpan, Mihaela Roxana
  • Rios-Mondragon, Ivan
  • Cimpan, Emil
  • Battistelli, Chiara
  • Bossa, Cecilia
  • Tsekovska, Rositsa
  • Drobne, Damjana
  • Novak, Sara
  • Repar, Neža
  • Ammar, Ammar
  • Nymark, Penny
  • Di Battista, Veronica
  • Sosnowska, Anita
  • Puzyn, Tomasz
  • Kochev, Nikolay
  • Iliev, Luchesar
  • Jeliazkov, Vedrin
  • Reilly, Katie
  • Lynch, Iseult
  • Bakker, Martine
  • Delpivo, Camila
  • Sánchez-Jiménez, A.
  • Fonseca, Ana Sofia
  • Manier, Nicolas
  • Fernández-Cruz, M. L.
  • Rashid, Shahzad
  • Willighagen, Egon L.
  • Apostolova, Margarita D.
  • Dusinska, Maria
43 Pág., Making research data findable, accessible, interoperable and reusable (FAIR) is typically hampered by a lack of skills in technical aspects of data management by data generators and a lack of resources. We developed a Template Wizard for researchers to easily create templates suitable for consistently capturing data and metadata from their experiments. The templates are easy to use and enable the compilation of machine-readable metadata to accompany data generation and align them to existing community standards and databases, such as eNanoMapper, streamlining the adoption of the FAIR principles. These templates are citable objects and are available as online tools. The Template Wizard is designed to be user friendly and facilitates using and reusing existing templates for new projects or project extensions. The wizard is accompanied by an online template validator, which allows self-evaluation of the template (to ensure mapping to the data schema and machine readability of the captured data) and transformation by an open-source parser into machine-readable formats, compliant with the FAIR principles. The templates are based on extensive collective experience in nanosafety data collection and include over 60 harmonized data entry templates for physicochemical characterization and hazard assessment (cell viability, genotoxicity, environmental organism dose-response tests, omics), as well as exposure and release studies. The templates are generalizable across fields and have already been extended and adapted for microplastics and advanced materials research. The harmonized templates improve the reliability of interlaboratory comparisons, data reuse and meta-analyses and can facilitate the safety evaluation and regulation process for (nano) materials., Supported by H2020 projects RiskGONE (no. 814425), HARMLESS (no. 953183), Gov4Nano (no. 814401), SABYDOMA (862296), SBD4NANO (862195), PLASTICFATE (no. 965367), POLYRISK (964766), NANOREG2 (no. 646221), PROPLANET (no. 101091842), NanoSolveIT (no. 814572), CompSafeNano (no. 101008099), TWINALT (no. 952404), VISION (no. 857381), KAPPA project EYFORTX2 (no. T001000099-PZ-2021), TEPCAN project (NCBR no. NOR/POLNOR/TEPCAN/0057/ 2019-00), hCOMET project (COST Action, CA 15132), Slovenian Research Agency projects P1-0207 and P1-0184, and by the Norwegian Research Council project NanoBioReal (no. 288768)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma

  • Urbanova, Maria
  • Viol, Fabrice
  • Ruiz-Cañas, Laura
  • Koniaris, Efthymios
  • Saksis, Rihards
  • Batres-Ramos, Sandra
  • Earl, Julie
  • Kataki, Agapi
  • Buocikova, Verona
  • Burikova, Monika
  • Cihova, Marina
  • Rojikova, Lucia
  • Makovicky, Peter
  • Matuskova, Miroslava
  • Kohl, Yvonne
  • Riedmayer, Andrea
  • Makova, Marianna
  • Baciak, Ladislav
  • Gogola, Daniel
  • Rogoza, Olesja
  • Rovite, Vita
  • Sainz, Bruno Jr.
  • Smolkova, Bozena
  • Schrader, Joerg
Chemotherapy with cisplatin (CDDP) and etoposide (ETO) is the standard treatment for gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). Despite high initial response rates, treatment-related toxicity and acquired resistance remain significant clinical challenges. No molecularly targeted therapies are currently established for this aggressive cancer. Here, we evaluated Aurora kinase inhibition with alisertib (ALI) as a synthetic lethality strategy in ARID1A-deficient GEP-NEC. Subcutaneous and orthotopic xenograft models were established in immunodeficient mice using the GEP-NEC-derived NT-38 cell line, and the therapeutic efficacy of ALI was compared with CDDP + ETO. Tumor responses were assessed by immunohistochemistry, Western blotting, and RNA sequencing. To confirm ARID1A dependency, transient knockdown was induced in the pancreatic neuroendocrine NT-18LM cell line, demonstrating that ALI sensitivity is significantly enhanced in ARID1A-deficient cells. ALI achieved antitumor efficacy comparable to chemotherapy and was well tolerated, with minimal weight loss relative to CDDP + ETO. Distant metastases, an early feature of GEP-NEC, developed in five animals over six weeks, two of which were treated with ALI and three controls. Transcriptomic profiling revealed convergence of both treatments on signal transduction, focal adhesion, receptor tyrosine kinase, and VEGFA-VEGFR2 signaling, while ALI uniquely enriched pathways related to pancreatic secretion, lipid metabolism, protein processing in the endoplasmic reticulum, and extracellular matrix organization. These findings establish Aurora kinase inhibition as mechanistically distinct and selectively effective in ARID1A-deficient GEP-NEC. Given its efficacy, favorable tolerability, and ARID1A-dependent specificity, ALI may represent a promising alternative to platinum-based chemotherapy, offering a strong rationale for further development of mechanism-driven combination strategies for GEP-NEC., This research was supported by the European Regional Development Fund through the “Establishing an Algorithm for the Early Diagnosis and Follow-Up of Patients with Pancreatic Neuroendocrine Tumors – NExT” project (1.1.1.5/ERANET/20/03), the European Union's Horizon 2020 research and innovation program under grant agreement No. 857381/VISION, COST action CA21116, funded by COST (European Cooperation in Science and Technology). German partners have been funded by a research grant to FV from the “Werner-Otto-Stiftung”. Slovak partners received funding from the Slovak Academy of Sciences (NExT-0711) and the Slovak Research and Development Agency (APVV-21-0197, APVV-20-0143). Greek partners were funded by the TRANSCAN-2 program ERA-NET JTC 2017 ″Translational Research on Rare Cancers” within the NExT project (NKUA), supported by the Ministry of Education, Research, and Religious Affairs – General Secretariat for Research and Technology, Greece (Τ9ΕРА3-00012). Support was also provided by the Spanish ISCIII-funded Biobank and Biomodels research and development platform grants in biomedicine and health sciences (PT23/00098) using Next Generation EU/PRTR funds., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening

  • Kohl, Yvonne
  • Biehl, Margit
  • Spring, Sarah
  • Hesler, Michelle
  • Ogourtsov, Vladimir
  • Todorovic, Miomir
  • Franco Puntes, Victor
(Nano) seguretat; Eficiència dels medicaments; Plataforma de microfluids, (Nano) seguridad; Eficiencia de los fármacos; Plataforma de microfluidos, (Nano)safety; Drug efficiency; Microfluidic platform, Microfluidic technology is a valuable tool for realizing more in vitro models capturing cellular and organ level responses for rapid and animal-free risk assessment of new chemicals and drugs. Microfluidic cell-based devices allow high-throughput screening and flexible automation while lowering costs and reagent consumption due to their miniaturization. There is a growing need for faster and animal-free approaches for drug development and safety assessment of chemicals (Registration, Evaluation, Authorisation and Restriction of Chemical Substances, REACH). The work presented describes a microfluidic platform for in vivo-like in vitro cell cultivation. It is equipped with a wafer-based silicon chip including integrated electrodes and a microcavity. A proof-of-concept using different relevant cell models shows its suitability for label-free assessment of cytotoxic effects. A miniaturized microscope within each module monitors cell morphology and proliferation. Electrodes integrated in the microfluidic channels allow the noninvasive monitoring of barrier integrity followed by a label-free assessment of cytotoxic effects. Each microfluidic cell cultivation module can be operated individually or be interconnected in a flexible way. The interconnection of the different modules aims at simulation of the whole-body exposure and response and can contribute to the replacement of animal testing in risk assessment studies in compliance with the 3Rs to replace, reduce, and refine animal experiments., T.K. and Y.K. contributed equally to this work. The authors thank Frank Bauerfeld for system assembly and electrical testing, Werner Haberer for assembly of the microfluidic cartridges, Axel Brenner for the fabrication of the silicon micro cavity chips, Hoffman La Roche for providing the Ro 19-8022, NorGenoTech for providing the Fpg enzyme, and Karen Steenson for proofreading. This research was funded by the European Commission under the Horizon2020 programme (HISENTS, Grant Agreement No. 685817 and VISION, Grant Agreement No. 857381); and by the Norwegian Research Council Norway (RCN) via the European Research Area Network (ERA-NET) EuroNanoMed II project INNOCENT (RCN 271075) and the ERA-NET EuroNanoMed III project Graphene-encapsulated magnetic nanoparticles (RCN 246672/O70). K.K. received Short Term Scientific Mission Grant (ID 42926) under COST Action CA 17140 “Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology). E.E. received funding from the Norwegian Research Council (272412/F40). O.H.M. received funding from the Spanish Ministry of Economy and Competitiveness (SEV-2013-0295-17-3).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro-In Vivo Correlation

  • Dubaj, Tibor
  • Kozics, Katarina
  • Sramkova, Monika
  • Manova, Alena
  • Bastús, Neus G
  • Moriones, Oscar Hernando
  • Franco Puntes, Victor
Gold nanoparticles; Human cell lines; Pharmacokinetics, Nanopartícules d'or; Línies cel·lulars humanes; Farmacocinètica, Nanopartículas de oro; Líneas celulares humanas; Farmacocinética, Data suitable for assembling a physiologically-based pharmacokinetic (PBPK) model for nanoparticles (NPs) remain relatively scarce. Therefore, there is a trend in extrapolating the results of in vitro and in silico studies to in vivo nanoparticle hazard and risk assessment. To evaluate the reliability of such approach, a pharmacokinetic study was performed using the same polyethylene glycol-coated gold nanoparticles (PEG-AuNPs) in vitro and in vivo. As in vitro models, human cell lines TH1, A549, Hep G2, and 16HBE were employed. The in vivo PEG-AuNP biodistribution was assessed in rats. The internalization and exclusion of PEG-AuNPs in vitro were modeled as first-order rate processes with the partition coefficient describing the equilibrium distribution. The pharmacokinetic parameters were obtained by fitting the model to the in vitro data and subsequently used for PBPK simulation in vivo. Notable differences were observed in the internalized amount of Au in individual cell lines compared to the corresponding tissues in vivo, with the highest found for renal TH1 cells and kidneys. The main reason for these discrepancies is the absence of natural barriers in the in vitro conditions. Therefore, caution should be exercised when extrapolating in vitro data to predict the in vivo NP burden and response to exposure., This research was funded by the European Commission under the Horizon 2020 programme (HISENTS, Grant Agreement No. 685817 and VISION, Grant Agreement No. 857381). Financial support from the Structural Funds of EU by implementation of the project “Strategic research in SMART monitoring, treatment, and prevention against coronavirus (SARS-CoV-2)”, ITMS 2014+ code NFP313011ASS8 co-financed by the European Regional Development Fund.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Microfluidic in vitro platform for (nano)safety and (nano)drug efficiency screening

  • Kohl, Yvonne|||0000-0001-8119-5441
  • Biehl, Margit
  • Spring, Sarah
  • Hesler, Michelle
  • Ogourtsov, Vladimir
  • Todorovic, Miomir
  • Owen, Joshua
  • Elje, Elisabeth
  • Kopecka, Kristina
  • Moriones, Oscar Hernando|||0000-0003-0310-0210
  • Bastús, Neus G.|||0000-0002-3144-7986
  • Šimon, Peter|||0000-0002-2828-4151
  • Dubaj, Tibor|||0000-0002-0290-7349
  • Rundén-Pran, Elise|||0000-0002-5541-4513
  • Puntes, Víctor|||0000-0001-8996-9499
  • William, Nicola
  • von Briesen, Hagen
  • Wagner, Sylvia
  • Kapur, Nikil
  • Mariussen, Espen|||0000-0001-5150-942X
  • Nelson, Andrew
  • Gabelova, Alena|||0000-0002-2674-2737
  • Dusinska, Maria|||0000-0003-1358-1652
  • Velten, Thomas
  • Knoll, Thorsten
Microfluidic technology is a valuable tool for realizing more in vitro models capturing cellular and organ level responses for rapid and animal-free risk assessment of new chemicals and drugs. Microfluidic cell-based devices allow high-throughput screening and flexible automation while lowering costs and reagent consumption due to their miniaturization. There is a growing need for faster and animal-free approaches for drug development and safety assessment of chemicals (Registration, Evaluation, Authorisation and Restriction of Chemical Substances, REACH). The work presented describes a microfluidic platform for in vivo-like in vitro cell cultivation. It is equipped with a wafer-based silicon chip including integrated electrodes and a microcavity. A proof-of-concept using different relevant cell models shows its suitability for label-free assessment of cytotoxic effects. A miniaturized microscope within each module monitors cell morphology and proliferation. Electrodes integrated in the microfluidic channels allow the noninvasive monitoring of barrier integrity followed by a label-free assessment of cytotoxic effects. Each microfluidic cell cultivation module can be operated individually or be interconnected in a flexible way. The interconnection of the different modules aims at simulation of the whole-body exposure and response and can contribute to the replacement of animal testing in risk assessment studies in compliance with the 3Rs to replace, reduce, and refine animal experiments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives

  • Buocikova, Verona
  • Rios-Mondragon, Ivan
  • Pilalis, Eleftherios|||0000-0002-5253-5256
  • Chatziioannou, Aristotelis|||0000-0003-2078-0844
  • Miklikova, Svetlana|||0000-0003-0692-1858
  • Mego, Michal
  • Pajuste, Karlis
  • Rucins, Martins
  • Yamani, Naouale El
  • Longhin, Eleonora Marta
  • Sobolev, Arkadij|||0000-0002-5517-1240
  • Freixanet Gustà, Muriel|||0000-0001-9872-3079
  • Puntes, Víctor|||0000-0001-8996-9499
  • Plotniece, Aiva|||0000-0003-2187-5693
  • Dusinska, Maria|||0000-0003-1358-1652
  • Cimpan, Mihaela Roxana
  • Gabelova, Alena|||0000-0002-2674-2737
  • Smolkova, Bozena|||0000-0002-4906-5652
Despite advances in cancer treatment, difficult-to-treat tumor subtypes remain a challenge. New multidisciplinary approaches can help overcome current obstacles posed by tumor heterogeneity, activation and enrichment of cancer stem cells, and acquired drug resistance development. Epigenome modulation, currently unsuccessful in solid tumors due to epigenetic drug instability, toxicity, and off-target effects, might be enabled by implementing nano-based delivery strategies aiming to improve breast cancer patient outcomes. Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacokinetics of PEGylated gold nanoparticles, in vitro-in vivo correlation

  • Dubaj, Tibor|||0000-0002-0290-7349
  • Kozics, Katarina|||0000-0002-6412-7962
  • Sramkova, Monika|||0000-0002-2758-2325
  • Manova, Alena|||0000-0002-4480-3556
  • Bastús, Neus G.|||0000-0002-3144-7986
  • Moriones, Oscar Hernando|||0000-0003-0310-0210
  • Kohl, Yvonne|||0000-0001-8119-5441
  • Dusinska, Maria|||0000-0003-1358-1652
  • Rundén-Pran, Elise|||0000-0002-5541-4513
  • Puntes, Víctor|||0000-0001-8996-9499
  • Nelson, Andrew
  • Gabelova, Alena|||0000-0002-2674-2737
  • Šimon, Peter|||0000-0002-2828-4151
Data suitable for assembling a physiologically-based pharmacokinetic (PBPK) model for nanoparticles (NPs) remain relatively scarce. Therefore, there is a trend in extrapolating the results of in vitro and in silico studies to in vivo nanoparticle hazard and risk assessment. To evaluate the reliability of such approach, a pharmacokinetic study was performed using the same polyethylene glycol-coated gold nanoparticles (PEG-AuNPs) in vitro and in vivo. As in vitro models, human cell lines TH1, A549, Hep G2, and 16HBE were employed. The in vivo PEG-AuNP biodistribution was assessed in rats. The internalization and exclusion of PEG-AuNPs in vitro were modeled as first-order rate processes with the partition coefficient describing the equilibrium distribution. The pharmacokinetic parameters were obtained by fitting the model to the in vitro data and subsequently used for PBPK simulation in vivo. Notable differences were observed in the internalized amount of Au in individual cell lines compared to the corresponding tissues in vivo, with the highest found for renal TH1 cells and kidneys. The main reason for these discrepancies is the absence of natural barriers in the in vitro conditions. Therefore, caution should be exercised when extrapolating in vitro data to predict the in vivo NP burden and response to exposure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacokinetics, biodistribution, and biosafety of PEGylated gold nanoparticles in vivo

  • Kozics, Katarina|||0000-0002-6412-7962
  • Sramkova, Monika|||0000-0002-2758-2325
  • Kopecka, Kristina
  • Begerova, Patricia
  • Manova, Alena|||0000-0002-4480-3556
  • Krivosikova, Zora|||0000-0002-1271-9923
  • Sevcikova, Zuzana
  • Liskova, Aurelia
  • Rollerova, Eva|||0000-0001-6317-2529
  • Dubaj, Tibor|||0000-0002-0290-7349
  • Puntes, Víctor|||0000-0001-8996-9499
  • Wsolova, Ladislava|||0000-0002-2229-0729
  • Šimon, Peter|||0000-0002-2828-4151
  • Tulinska, Jana|||0000-0001-9661-8654
  • Gabelova, Alena|||0000-0002-2674-2737
Despite the obvious advantages of gold nanoparticles for biomedical applications, controversial and incomplete toxicological data hamper their widespread use. Here, we present the results from an in vivo toxicity study using gold nanoparticles coated with polyethylene glycol (PEG-AuNPs). The pharmacokinetics and biodistribution of PEG-AuNPs were examined in the rat's liver, lung, spleen, and kidney after a single i.v. injection (0.7 mg/kg) at different time intervals. PEG-AuNPs had a relatively long blood circulation time and accumulated primarily in the liver and spleen, where they remained for up to 28 days after administration. Increased cytoplasmic vacuolation in hepatocytes 24 h and 7 days after PEG-AuNPs exposure and apoptotic-like cells in white splenic pulp 24 h after administration has been detected, however, 28 days post-exposure were no longer observed. In contrast, at this time point, we identified significant changes in lipid metabolism, altered levels of liver injury markers, and elevated monocyte count, but without marked biological relevance. In blood cells, no DNA damage was present in any of the studied time intervals, with the exception of DNA breakage transiently detected in primary kidney cells 4 h post-injection. Our results indicate that the tissue accumulation of PEG-AuNPs might result in late toxic effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gold and titania nanoparticles accumulated in the body induce late toxic effects and alterations in transcriptional and miRNA landscape

  • Soltysova, Andrea|||0000-0002-1402-3583
  • Ludwig, Nicole|||0000-0003-4703-7567
  • Diener, Caroline|||0000-0002-3222-8419
  • Sramkova, Monika|||0000-0002-2758-2325
  • Kozics, Katarina|||0000-0002-6412-7962
  • Jakic, Kristina|||0000-0002-8251-5328
  • Balintova, Lucia
  • Bastús, Neus G.|||0000-0002-3144-7986
  • Moriones, Oscar Hernando|||0000-0003-0310-0210
  • Liskova, Aurelia
  • Krivosikova, Zora|||0000-0002-1271-9923
  • Rollerova, Eva|||0000-0001-6317-2529
  • Manova, Alena|||0000-0002-4480-3556
  • Dubaj, Tibor|||0000-0002-0290-7349
  • Puntes, Víctor|||0000-0001-8996-9499
  • Šimon, Peter|||0000-0002-2828-4151
  • Wsolova, Ladislava|||0000-0002-2229-0729
  • Tulinska, Jana|||0000-0001-9661-8654
  • Smolkova, Bozena|||0000-0002-4906-5652
  • Meese, Eckart|||0000-0001-7569-819X
  • Gabelova, Alena|||0000-0002-2674-2737
The growing production of nanomaterials and their presence in consumer products raises fear about their impact on human health and the environment. Of particular concern are those nanomaterials that exhibit poor excretion and tend to accumulate in living organisms. Our study investigated the potential adverse biological effects of residual gold and titania nanoparticles (PEG-AuNPs and TiONPs) 28 days after a single intravenous administration in rats. To comprehensively assess the potential health hazard of these metal nanoparticles (MNP), toxicological and transcriptomic analyses were employed. The liver was the primary organ of the MNP deposition, causing a reduction in the relative liver weight compared to unexposed animals. Concurrently, changes in serum biomarkers indicative of hepatic dysfunction and hematological and immunological alternations were determined. Integrated transcriptomic analysis unveiled exposure-induced effects on the rats' lungs, liver, and kidneys. The hepatic tissue, particularly in PEG-AuNPs-exposed rats, exhibited a noteworthy prevalence of deregulated genes, with functional classification spanning lipid metabolism, cell cycle, and cell proliferation pathways. Although the number of deregulated miRNAs was relatively modest compared to mRNA expression changes, both types of MNPs deregulated miR-203a, associated with liver injury, and miR-18a-5p and miR-32-5p linked to kidney damage. This study underscores the imperative for a more exhaustive biosafety assessment of poorly soluble MNPs that tend to deposit in the body. Such investigations are crucial for delineating the potential risks of these nanomaterials and guiding the development of adequate safety measures in their production and usage.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening

  • Kohl, Yvonne
  • Biehl, Margit
  • Spring, Sarah
  • Hesler, Michelle
  • Ogourtsov, Vladimir
  • Todorovic, Miomir
  • Franco Puntes, Victor
(Nano) seguretat; Eficiència dels medicaments; Plataforma de microfluids, (Nano) seguridad; Eficiencia de los fármacos; Plataforma de microfluidos, (Nano)safety; Drug efficiency; Microfluidic platform, Microfluidic technology is a valuable tool for realizing more in vitro models capturing cellular and organ level responses for rapid and animal-free risk assessment of new chemicals and drugs. Microfluidic cell-based devices allow high-throughput screening and flexible automation while lowering costs and reagent consumption due to their miniaturization. There is a growing need for faster and animal-free approaches for drug development and safety assessment of chemicals (Registration, Evaluation, Authorisation and Restriction of Chemical Substances, REACH). The work presented describes a microfluidic platform for in vivo-like in vitro cell cultivation. It is equipped with a wafer-based silicon chip including integrated electrodes and a microcavity. A proof-of-concept using different relevant cell models shows its suitability for label-free assessment of cytotoxic effects. A miniaturized microscope within each module monitors cell morphology and proliferation. Electrodes integrated in the microfluidic channels allow the noninvasive monitoring of barrier integrity followed by a label-free assessment of cytotoxic effects. Each microfluidic cell cultivation module can be operated individually or be interconnected in a flexible way. The interconnection of the different modules aims at simulation of the whole-body exposure and response and can contribute to the replacement of animal testing in risk assessment studies in compliance with the 3Rs to replace, reduce, and refine animal experiments., T.K. and Y.K. contributed equally to this work. The authors thank Frank Bauerfeld for system assembly and electrical testing, Werner Haberer for assembly of the microfluidic cartridges, Axel Brenner for the fabrication of the silicon micro cavity chips, Hoffman La Roche for providing the Ro 19-8022, NorGenoTech for providing the Fpg enzyme, and Karen Steenson for proofreading. This research was funded by the European Commission under the Horizon2020 programme (HISENTS, Grant Agreement No. 685817 and VISION, Grant Agreement No. 857381); and by the Norwegian Research Council Norway (RCN) via the European Research Area Network (ERA-NET) EuroNanoMed II project INNOCENT (RCN 271075) and the ERA-NET EuroNanoMed III project Graphene-encapsulated magnetic nanoparticles (RCN 246672/O70). K.K. received Short Term Scientific Mission Grant (ID 42926) under COST Action CA 17140 “Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology). E.E. received funding from the Norwegian Research Council (272412/F40). O.H.M. received funding from the Spanish Ministry of Economy and Competitiveness (SEV-2013-0295-17-3).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro-In Vivo Correlation

  • Dubaj, Tibor
  • Kozics, Katarina
  • Sramkova, Monika
  • Manova, Alena
  • Bastús, Neus G
  • Moriones, Oscar Hernando
  • Franco Puntes, Victor
Gold nanoparticles; Human cell lines; Pharmacokinetics, Nanopartícules d'or; Línies cel·lulars humanes; Farmacocinètica, Nanopartículas de oro; Líneas celulares humanas; Farmacocinética, Data suitable for assembling a physiologically-based pharmacokinetic (PBPK) model for nanoparticles (NPs) remain relatively scarce. Therefore, there is a trend in extrapolating the results of in vitro and in silico studies to in vivo nanoparticle hazard and risk assessment. To evaluate the reliability of such approach, a pharmacokinetic study was performed using the same polyethylene glycol-coated gold nanoparticles (PEG-AuNPs) in vitro and in vivo. As in vitro models, human cell lines TH1, A549, Hep G2, and 16HBE were employed. The in vivo PEG-AuNP biodistribution was assessed in rats. The internalization and exclusion of PEG-AuNPs in vitro were modeled as first-order rate processes with the partition coefficient describing the equilibrium distribution. The pharmacokinetic parameters were obtained by fitting the model to the in vitro data and subsequently used for PBPK simulation in vivo. Notable differences were observed in the internalized amount of Au in individual cell lines compared to the corresponding tissues in vivo, with the highest found for renal TH1 cells and kidneys. The main reason for these discrepancies is the absence of natural barriers in the in vitro conditions. Therefore, caution should be exercised when extrapolating in vitro data to predict the in vivo NP burden and response to exposure., This research was funded by the European Commission under the Horizon 2020 programme (HISENTS, Grant Agreement No. 685817 and VISION, Grant Agreement No. 857381). Financial support from the Structural Funds of EU by implementation of the project “Strategic research in SMART monitoring, treatment, and prevention against coronavirus (SARS-CoV-2)”, ITMS 2014+ code NFP313011ASS8 co-financed by the European Regional Development Fund.